uniQure Announces Presentations at Upcoming April Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 03, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced presentations at the following conferences taking place in April:

World Orphan Drug Congress USA, April 19 – 21 2017, at the Washington Marriott Wardman Park in Washington D.C.

• Matt Kapusta, Chief Executive Officer, will be presenting a keynote address: Adeno-associated virus (AAV)-based gene therapies for rare, chronic and degenerative diseases, on Friday April 21^st, 2017, 9.40 a.m. EDT.

12th Annual HD Therapeutics Conference by CHDI, April 24 – 27 2017, at the Westin Dragonara Resort in St. Julian’s, Malta.

• A presentation new preclinical data on huntingtin gene silencing in a mini-pig model of Huntington’s Disease, using allele-specific and non-selective miRNAs, will be presented during the CHDI conference.

Gene Therapy for Rare Disorders Conference, April 25 – 26 2017, at the Sheraton Boston Hotel, in Boston MA.

• Lance Weed, Vice President of US Operations, will be presenting: Optimizing the Scalability of Gene Therapy Manufacturing, on Tuesday April 25^th, 2017, 2.00 p.m. EDT.
• Eileen Sawyer, Director of Global Medical Affairs, will be presenting: Bridging Gaps Through Early Integration of the Internal Medical Affairs Function, on Wednesday April 26^th, 2017, 11.00 a.m. EDT.
• Daniel Leonard, Director of Global Patient Advocacy, will be presenting: The Intersection of Patient Advocacy and Gene Therapy: A Case Study in Hemophilia, on Wednesday April 26^th, 2017, 2.00 p.m. EDT.

Alliance for Regenerative Medicines (ARM)’s 5^th Annual Cell & Gene Therapy Investor Day, April 27^th 2017, at The State Room, in Boston MA.

• Matthew Kapusta, chief executive officer, will be participating in a fireside chat on Thursday, April 27^th, 2017, 2.15 p.m. EDT.

The Company also announced its participation in the following conferences taking place in April:

Hemophilia Federation of America (HFA)’s Annual Symposium, April 6 – 9 2017, at the Rhode Island Convention Center in Providence, RI.

The International Liver Congress 2017 by EASL, April 19 – 23 2017 at the RAI in Amsterdam, The Netherlands.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com

uniQure Contacts:

Maria E. Cantor		
Direct: 339-970-7536	
Mobile:  617-680-9452	
[email protected] 	

Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79 
[email protected] 

Tom Malone
Direct:  339-970-7558
Mobile:  339-223-8541
[email protected]